{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-048907","form_type":"8-K","ticker":"SIGA","cik":"0001010086","company_name":"SIGA TECHNOLOGIES INC","filed_at":"2024-12-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.350634+00:00","generated_at":"2026-05-29T04:58:50.772926+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"SIGA's tecovirimat fails mpox lesion resolution endpoint; STOMP enrollment stopped","bullets":["Tecovirimat did not improve time to lesion resolution vs placebo in mild to moderate clade II mpox; DSMB recommended stop enrollment.","Enrollment halted in all study arms including open-label for severe patients; data analysis ongoing for secondary endpoints.","Safety profile affirmed as comparable to placebo, consistent with prior studies over 15 years.","CEO stated ~75% of randomized patients received drug >5 days after symptom onset; early treatment may offer benefit.","Company expects three ongoing trials (UNITY, Platinum-CAN, EPOXI) to yield similar results given design parallels."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-048907","json":"https://secwatch.observer/filing/0001140361-24-048907.json","markdown":"https://secwatch.observer/filing/0001140361-24-048907.md","text":"https://secwatch.observer/filing/0001140361-24-048907.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1010086/000114036124048907/0001140361-24-048907-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1010086/000114036124048907/ef20039836_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:58:50.772926+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}